This journal is a member of the Committee on Publication Ethics (COPE).
The Journal of Psoriasis and Psoriatic Arthritis (JPPA) is a quarterly, peer-reviewed, specialty journal published by the National Psoriasis Foundation (NPF). The journal disseminates the latest clinical, translational, and basic research and practical treatment information about psoriasis, psoriatic arthritis, as well as related comorbidities and conditions. The goal of the JPPA is to provide readers with knowledge that advances their expertise, a goal accomplished by publishing evidence-based research.
JPPA publishes original research, review articles, case studies, commentary, and brief reports on all aspects of psoriatic disease including basic research, evaluation and diagnosis, heredity, pharmacotherapy, and symptom management.
Diversity, Equity, and Inclusion:
Psoriatic disease doesn’t discriminate. NPF advocates for improved access to care and meaningful access to treatments for all. JPPA is passionate about supporting diversity, equity, and inclusion in wider society through our publishing activities, which include ensuring diversity (ethnic and gender) in our editorial board, peer reviewers, and author base.
|Bruce Strober, MD, PhD||Clinical Professor of Dermatology, Yale University, New Haven, CT; Central Connecticut Dermatology, Cromwell, CT, USA|
|Alice B. Gottlieb, MD, PhD||Icahn School of Medicine at Mount Sinai, New York, NY, USA|
|John Y. M. Koo, MD||University of California-San Francisco Medical Center, San Francisco, CA, USA|
|Mark Lebwohl, MD||Icahn School of Medicine at Mount Sinai, New York, NY, USA|
|April Armstrong, MD, MPH||Keck School of Medicine, Clinical and Translational Science Institute, University of Southern California, Los Angeles, CA, USA|
|Andy Blauvelt, MD, MBA||Oregon Medical Research Center, Portland, OR, USA|
|Megan H. Noe, MD, MPH, MSCE||Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA|
|Mona Shahriari, MD, FAAD||Yale University, New Haven, CT; Central CT Dermatology, Cromwell, CT, USA|
|Lakshi Aldredge, MSN, ANP-C||VA Portland Health Care System, Portland, OR, USA|
|Herve Bachelez, MD, PhD||Hôpital Saint-Louis Sorbonne Paris Cité, Université Paris Diderot, Paris, France|
|Jerry Bagel, MD||Psoriasis Treatment Center of Central New Jersey, East Windsor, NJ, USA|
|Luca Bianchi, MD||University of Rome Tor Vergata, Rome, Italy|
|David R. Bickers, MD||Columbia University Medical Center, New York, NY, USA|
|Robert Bissonnette, MD||University of Montreal Hospital Centre, Montreal, Canada|
|Erin Boh, MD, PhD||Tulane University School of Medicine, New Orleans, LA, USA|
|Anne M. Bowcock, PhD||Icahn School of Medicine at Mount Sinai, New York, NY, USA|
|Jeffrey P. Callen, MD||University of Louisville, Louisville, KY, USA|
|Vinod Chandran, MBBS, MD, DM, PhD||University of Toronto, Department of Medicine, Division of Rheumatology, Toronto Western Hospital, Toronto, ON, Canada|
|Robin Christensen, BSc, MSc, PhD||The Parker Institute, Copenhagen, Denmark|
|Kelly Cordoro, MD||University of California, San Francisco, CA, USA|
|Jeffrey Crowley, MD||Bakersfield Dermatology, Bakersfield, CA, USA|
|Kristina Callis Duffin, MD||The University of Utah, Salt Lake City, UT, USA|
|Lawrence Eichenfield, MD||University of California, San Diego, CA, USA|
|Charles N. Ellis, MD||University of Michigan Medical School, Ann Arbor, MI, USA|
|Steven Feldman, MD, PhD||Wake Forest Baptist Medical Center, Winston-Salem, NC, USA|
|Hassan Galadari, MD||College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates|
|Joel Gelfand, MD, MSCE||University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA|
|Dafna D. Gladman, MD||University of Toronto; Krembil Research Institute; Centre for Prognosis Studies in Rheumatic Diseases, University Health Network, Toronto Western Hospital, Toronto, Canada|
|Kenneth Gordon, MD||Medical College of Wisconsin, Milwaukee, WI, USA|
|Chris Griffiths, MB, MD||University of Manchester, Manchester, UK|
|Percio Gulko, MD||Icahn School of Medicine at Mount Sinai, New York, NY, USA|
|Philip Helliwell, MD||University of Leeds, Leeds, UK|
|Sylvia Hsu, MD||Baylor College of Medicine Houston, Houston, TX, USA|
|Abby Jacobson, MS, PA-C||Delaware Valley Dermatology Group, LLC, Wilmington, DE, USA|
|Joseph L. Jorizzo, MD||Wake Forest University School of Medicine, Winston-Salem, NC, USA; Weill Cornell Medical College, New York, NY, USA|
|Arthur Kavanaugh, MD||University of California, San Diego, CA, USA|
|Neil Korman, MD, PhD||University Hospitals Cleveland Medical Center, Cleveland, OH, USA|
|Gerald G. Krueger, MD||University of Utah School of Medicine, Salt Lake City, UT, USA|
|Richard Langley, MD||Dalhousie University, Halifax, NS, Canada|
|Thomas McCormick, PhD||Case Western Reserve University, Cleveland, OH, USA|
|Philip Mease, MD||University of Washington, Seattle, WA, USA|
|Nehal N. Mehta, MD, MSCE||National Heart, Lung and Blood Institute, Bethesda, MD, USA|
|Luigi Naldi, MD||Hospital San Bortolo, Vicenza, Italy|
|Amy Paller, MD||Northwestern University, Chicago, IL, USA|
|Kim Papp, MD, PhD||Probity Medical Research, Inc., Ontario, Canada|
|Lourdes M. Perez-Chada, MD, MMSc||International Dermatology Outcome Measures (IDEOM) Research Fellow; Psoriasis and Psoriatic Arthritis Clinical Research Fellow; Brigham and Women's Hospital-Harvard Medical School, Boston, MA, USA|
|Jörg Prinz, MD||Ludwig Maximilian University, Munich, Germany|
|Ronald Prussick, MD||George Washington University, Washington D.C., USA|
|Lluís Puig, MD, PhD||Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain|
|Abrar Qureshi, MD, MPH||Brown University, Providence, RI, USA|
|Kristian Reich, MD, PhD||Dermatologikum Hamburg, Hamburg, Germany|
|Cheryl Rosen, MD, FRCPC||University of Toronto, Toronto, Canada|
|David Rosmarin, MD||Tufts Medical Center, Boston, MA, USA|
|Eric Ruderman, MD||Northwestern Feinberg School of Medicine, Chicago, IL, USA|
|Caitriona Ryan, MD, FAAD||St. Vincent's University Hospital, Blackrock Clinic, Dublin, Ireland|
|Enrique Soriano, MD, MS||Hospital Italiano de Buenos Aires, Buenos Aires, Argentina|
|Mona Ståhle, MD, PhD||Karolinska Institutet, Stockholm, Sweden|
|Stephen Stone, MD, FAAD||SIU Medicine, Springfield, IL, USA|
|Paul Tebbey, PhD, MBA||AbbVie, Chicago, IL, USA|
|Abby Van Voorhees, MD||Eastern Virginia Medical School, Norfolk, VA, USA|
|John E. Wolf Jr., MA, MD||Baylor College of Medicine, Houston, TX, USA|
|Jashin J. Wu, MD||Dermatology Research and Education Foundation, Irvine, CA, USA|
|Melodie Young, MSN, ANP-C||Modern Dermatology and Modern Research Associates, Dallas, TX, USA|
Please read the guidelines below, then visit the submission site for Journal of Psoriasis and Psoriatic Arthritis (JPPA) at https://mc.manuscriptcentral.com/JPPA to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned. Remember you can log in to the submission site at any time to check on the progress of your paper through the peer review process.
Psoriatic disease doesn't discriminate. NPF advocates for improved access to care and meaningful access to treatments for all. JPPA is passionate about supporting diversity, equity, and inclusion in wider society through our publishing activities, which include diversity (ethnic and gender) in our editorial board, peer reviewers, and author base.
SAGE Publishing disseminates high-quality research and engaged scholarship globally, and we are committed to diversity and inclusion in publishing. We encourage submissions from a diverse range of authors from across all countries and backgrounds.
Only manuscripts of sufficient quality that meet the aims and scope of the Journal will be reviewed.
As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere. Please see our guidelines on prior publication and note that JPPA may accept submissions of papers that have been posted on pre-print servers; please alert the Editorial Office when submitting (contact details are at the end of these guidelines) and include the DOI for the preprint in the designated field in the manuscript submission system. Authors should not post an updated version of their paper on the preprint server while it is being peer reviewed for possible publication in the journal. If the article is accepted for publication, the author may re-use their work according to the journal's author archiving policy. If your paper is accepted, you must include a link on your preprint to the final version of your paper.
This Journal is a member of the Committee on Publication Ethics.
This Journal recommends that authors follow the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals formulated by the International Committee of Medical Journal Editors (ICMJE).
There are no fees payable to submit or publish in this journal.
If you have any questions about publishing with SAGE, please visit the SAGE Journal Solutions Portal.
- What we Publish
1.1 Aims & Scope
1.2 Article Types
1.3 Writing Your Paper
1.3.1 Make Your Article Discoverable
- Editorial Policies
2.1 Peer Review Policy
2.3.1 Third party submissions
2.3.2 Writing Assistance
2.5 Declaration of Conflicting Interests
2.6 Research Ethics and Patient Consent
2.7 Clinical Trials
2.8 Reporting Guidelines
2.9 Research Data
- Publishing Policies
3.1 Publication Ethics
3.1.2 Prior Publication
3.2 Contributor's Publishing Agreement
3.3 Open Access and Author Archiving
- Preparing your Manuscript
4.2 Artwork, Figures and Other Graphics
4.3 Supplemental Material
4.4 Journal Layout
4.5 Reference Style
4.6 English Language Editing Services
- Submitting your Manuscript
5.2 Title, Keywords and Abstracts
5.3 Information Required for Completing Your Submission
- On Acceptance and Publication
6.1 SAGE Production
6.2 OnlineFirst Publication
6.3 Access to your Published Article
6.4 Promoting Your Article
- Further information
7.1 Appealing the publication decision
Before submitting your manuscript to JPPA, please ensure you have read the Aims & Scope.
Manuscripts submitted to the Journal of Psoriasis and Psoriatic Arthritis should be of general interest to researchers and medical professionals specializing in psoriatic disease research and patient care. Articles are typically 900 to 3,000 words long, but longer articles will be considered.
Reports of Original Research
Original, in-depth clinical and investigative laboratory research papers focused on the fundamental cause and treatment of psoriatic diseases.
Reviews of literature, clinical trials, or patterns appearing in cases of psoriasis and psoriatic arthritis pertinent to factors such as the cause, diagnosis, prognosis, or therapy of these diseases.
In-depth review of a therapeutic modality or treatment procedure for the treatment of psoriasis or psoriatic arthritis.
Brief Reports and Abstracts
Brief clinical observations, reports of studies, or evaluations that are unique to the care of psoriasis or psoriatic arthritis.
Brief individual cases of psoriasis or psoriasis treatment of unusual interest.
Editorials and Commentaries
Brief, provocative, opinionated communications on issues pertinent to the treatment and care of psoriasis or psoriatic arthritis.
The SAGE Author Gateway has some general advice and on how to get published, plus links to further resources.
For information and guidance on how to make your article more discoverable, visit our Gateway page on How to Help Readers Find Your Article Online.
Journal of Psoriasis and Psoriatic Arthritis is a peer-reviewed specialty journal published by the National Psoriasis Foundation for its professional members and for dermatology and rheumatology specialists. The purpose of the journal is to provide the latest research and practical treatment information about psoriasis and psoriatic arthritis in a concise and easy-to-read format. Medical professionals are invited to submit articles to be considered for publication. JPPA recommends that authors follow the Uniform Requirements for Manuscripts Submitted to Biomedical Journals formulated by the International Committee of Medical Journal Editors (ICMJE).Manuscripts selected for publication will be published in the print and online version of the Journal.
DISCLAIMER: The National Psoriasis Foundation is a 501(c)(3) lay, patient-driven nonprofit organization with a mission to drive efforts to cure psoriatic disease and improve the lives of those affected. Opinions expressed in this publication are those of the author(s) and do not necessarily reflect the view of the National Psoriasis Foundation, its Board of Directors, or its Medical Board. Only original articles will be considered for publication in JPPA. Please do not submit articles that are being submitted to other journals.
JPPA operates a conventional single-anonymized reviewing policy in which the reviewer’s name is always concealed from the submitting author.
The editorial staff will review the manuscript and, if it meets JPPA’s editorial standards, will send it to at least two reviewers. Reviewers will pay particular attention to scientific accuracy, relevance, novelty, importance, appropriate style, and whether the article would be of general interest to medical professionals and researchers focused on psoriasis or psoriatic arthritis. Decisions on manuscripts will be made as rapidly as possible.
Some degree of manuscript revision should be expected and regarded as constructive. A request to submit a revised manuscript does not guarantee that it will be accepted; rather this means only that it will be reconsidered, perhaps after additional peer review. The final editorial decision rests not only on the validity of the report and the opinions of the reviewers, but also on the editors’ judgment of the article’s novelty, clarity, importance, and likely degree of interest to the readership.
The Editor or members of the Editorial Board may occasionally submit their own manuscripts for possible publication in the Journal. In these cases, the peer review process will be managed by alternative members of the Board and the submitting Editor/Board member will have no involvement in the decision-making process.
SAGE does not permit the use of author-suggested (recommended) reviewers at any stage of the submission process, be that through the web-based submission system or other communication. Reviewers should be experts in their fields and should be able to provide an objective assessment of the manuscript. Our policy is that reviewers should not be assigned to a paper if:
• The reviewer is based at the same institution as any of the co-authors
• The reviewer is based at the funding body of the paper
• The author has recommended the reviewer
• The reviewer has provided a personal (e.g. Gmail/Yahoo/Hotmail) email account and an institutional email account cannot be found after performing a basic Google search (name, department and institution).
JPPA is committed to delivering high quality, fast peer-review for your paper, and thus has partnered with Publons. Publons is a third party service that seeks to track, verify and give credit for peer review. Reviewers for JPPA can opt in to Publons in order to claim their reviews or have them automatically verified and added to their reviewer profile. Reviewers claiming credit for their review will be associated with the relevant journal, but the article name, reviewer’s decision and the content of the review is not published on the site. For more information visit the Publons website.
Papers should only be submitted for consideration once consent is given by all contributing authors. Those submitting papers should carefully check that all those whose work contributed to the paper are acknowledged as contributing authors.
The list of authors should include all those who can legitimately claim authorship. This is all those who:
- Made a substantial contribution to the concept and design, acquisition of data or analysis and interpretation of data,
- Drafted the article or revised it critically for important intellectual content,
- Approved the version to be published.
Authors should meet the conditions of all of the points above. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.
One author should be designated as the corresponding author, with that author’s complete address, telephone and fax numbers, and e-mail address provided on the title page. The JPPA editor will correspond only with the corresponding author.
When a large, multicentre group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship.
Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship, although all contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section.
Please refer to the International Committee of Medical Journal Editors (ICMJE) authorship guidelines for more information on authorship.
All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.
Any acknowledgements should appear first at the end of your article prior to your Declaration of Conflicting Interests (if applicable), any notes and your References.
Where an individual who is not listed as an author submits a manuscript on behalf of the author(s), a statement must be included in the Acknowledgements section of the manuscript and in the accompanying cover letter. The statements must:
- Disclose this type of editorial assistance – including the individual’s name, company and level of input
- Identify any entities that paid for this assistance
- Confirm that the listed authors have authorized the submission of their manuscript via third party and approved any statements or declarations, e.g. conflicting interests, funding, etc.
Where appropriate, SAGE reserves the right to deny consideration to manuscripts submitted by a third party rather than by the authors themselves.
2.3.2 Writing Assistance
Individuals who provided writing assistance, e.g. from a specialist communications company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company and level of input – and identify the entity that paid for this assistance).
It is not necessary to disclose use of language polishing services.
The Journal requires all authors to acknowledge their funding in a consistent fashion under a separate heading. Please visit the Funding Acknowledgements page on the SAGE Journal Author Gateway to confirm the format of the acknowledgment text in the event of funding, or state that: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
It is the policy of JPPA to require a declaration of conflicting interests from all authors enabling a statement to be carried within the paginated pages of all published articles.
The Journal requires all authors to acknowledge all funding sources that supported their work as well as all institutional or corporate affiliations of the authors. These include but are not limited to employment, royalties, consulting arrangements with a commercial entity, stock or other equity ownership, stock options, patent licensing arrangements, payments for conducting or publicizing a product or study, or consulting relationships with investment companies. In addition, authors are required to disclose similar associations with companies that make a competing product.
Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of your manuscript, after any acknowledgements and prior to the references. If no conflict exists, please state that ‘The Author(s) declare(s) that there is no conflict of interest’.
The Editors also require the reviewer to disclose any competing interests or conflicts of interest that might interfere with their objectivity (or to recuse oneself from acting as a reviewer). The Editors and members of the editorial staff have registered their competing interests with the National Psoriasis Foundation. The Editors and members of the editorial staff will ensure that all conflicts are appropriately resolved. Conflicts that cannot be appropriately resolved will result in rejection of the manuscript or review. Undisclosed conflicts may result in sanctions.
For guidance on conflict of interest statements, please see the ICMJE recommendations here.
Medical research involving human subjects must be conducted according to the World Medical Association Declaration of Helsinki.
Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting animal and/or human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number. A copy of the IRB approval letter must be included with the submission or sent to the JPPA editor under separate cover.
For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal. If applicable, IRB approval must be mentioned in the methods section of all manuscripts. If the methods section is not sufficiently clear, authors may be asked to provide the editors with a copy of IRB-approved research protocols for the use of our reviewers.
Patients must not be identified by name or initials; numbers should be used. No other information, including clinical photos or family trees from which a patient could be identified, is permitted unless express written permission from the patient or family is provided at the time of manuscript submission.
Information on informed consent to report individual cases or case series should be included in the manuscript text. A statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative. Please do not submit the patient’s actual written informed consent with your article, as this in itself breaches the patient’s confidentiality. The Journal requests that you confirm to us, in writing, that you have obtained written informed consent but the written consent itself should be held by the authors/investigators themselves, for example in a patient’s hospital record. The confirmatory letter may be uploaded with your submission as a separate file.
Please also refer to the ICMJE Recommendations for the Protection of Research Participants.
Special Requirements for Studies Involving Animal Subjects
All research involving animals submitted for publication must be approved by an ethics committee with oversight of the facility in which the studies were conducted. The Journal has adopted the ARRIVE guidelines.
JPPA conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrollment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.
The relevant EQUATOR Network reporting guidelines should be followed depending on the type of study. For example, all randomized controlled trials submitted for publication should include a completed Consolidated Standards of Reporting Trials (CONSORT) flow chart as a cited figure, and a completed CONSORT checklist as a supplementary file. If your research involves animals, you will be asked to confirm that you have carefully read and adhered to the ARRIVE guidelines
Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives.
The journal is committed to facilitating openness, transparency and reproducibility of research, and has the following research data sharing policy. For more information, including FAQs please visit the SAGE Research Data policy pages.
Subject to appropriate ethical and legal considerations, authors are encouraged to:
- share your research data in a relevant public data repository
- include a data availability statement linking to your data. If it is not possible to share your data, we encourage you to consider using the statement to explain why it cannot be shared.
- cite this data in your research
SAGE is committed to upholding the integrity of the academic record. We encourage authors to refer to the Committee on Publication Ethics’ International Standards for Authors and view the Publication Ethics page on the SAGE Author Gateway.
JPPA and SAGE take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of articles published in the journal. Equally, we seek to protect the reputation of the journal against malpractice. Submitted articles may be checked using duplication-checking software. Where an article is found to have plagiarised other work or included third-party copyright material without permission or with insufficient acknowledgement, or where authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article (removing it from the journal); taking up the matter with the head of department or dean of the author’s institution and/or relevant academic bodies or societies; banning the author from publication in the journal or all SAGE journals, or appropriate legal action.
If material has been previously published it is not generally acceptable for publication in a SAGE journal. However, there are certain circumstances where previously published material can be considered for publication. Please refer to the guidance on the SAGE Author Gateway or if in doubt, contact the Editor at the address given below.
Before publication, SAGE requires the author as the rights holder to sign a Journal Contributor’s Publishing Agreement. SAGE’s Journal Contributor’s Publishing Agreement is an exclusive licence agreement which means that the author retains copyright in the work but grants SAGE the sole and exclusive right and licence to publish for the full legal term of copyright. Exceptions may exist where an assignment of copyright is required or preferred by a proprietor other than SAGE. In this case copyright in the work will be assigned from the author to the society. For more information please visit our Frequently Asked Questions on the SAGE Journal Author Gateway.
Journal of Psoriasis and Psoriatic Arthritis offers optional open access publishing via the SAGE Choice programme. For more information on Open Access publishing options at SAGE please visit SAGE Open Access. For information on funding body compliance, and depositing your article in repositories, please visit SAGE’s Author Archiving and Re-Use Guidelines and Publishing Policies.
Preferred formats for the text and tables of your manuscript are Word DOC, RTF, XLS. Please line-number all manuscripts. Manuscripts must be typed, double-spaced, with 1-inch or larger margins throughout, including title page, text, references, legends for illustrations, and tables. Text should be standard 10 or 12 point.
For guidance on the preparation of illustrations, pictures and graphs in electronic format, please visit SAGE’s Manuscript Submission Guidelines.
Figures supplied in color will appear in color online regardless of whether or not these illustrations are reproduced in color in the printed version. For specifically requested color reproduction in print, you will receive information regarding the costs from SAGE after receipt of your accepted article.
The National Psoriasis Foundation encourages authors to submit relevant graphic elements, such as photographs, charts, tables, and illustrations. Authors are responsible for seeking permission to republish above-named graphic elements that have been previously published.
This journal is able to host additional materials online (e.g. datasets, podcasts, videos, images, etc.) alongside the full-text of the article. These will be subjected to peer-review alongside the article. For more information please refer to our guidelines on submitting supplemental files.
JPPA conforms to the AMA Manual of Style. Please also follow the instructions below.
The title page shall include: (1) the title, (2) authors’ names, (3) authors’ highest earned academic degrees, (4) institutional affiliations and locations, (5) corresponding author information, (6) statement of funding sources and any authors’ conflicts of interest and, (7) word count, figure count, and number of references.
All articles must be accompanied by an abstract not exceeding 250 words. The abstract should concisely summarize the major points and purpose of the manuscript and its key conclusions. The abstract should be structured into sections: Background, Objective, Methods, Results, and Conclusion. The abstract should not contain any references.
A list of five to eight key words should appear after the abstract.
Abbreviations and Acronyms
Only standard abbreviations are to be used. Consult the Manual of Style by the American Medical Association. Abbreviations in the title are not acceptable, and they should be avoided in the abstract. A laboratory or chemical term or a disease process must be spelled out on first reference, with the acronym or abbreviation following in parentheses. The abbreviation or acronym should be used thereafter except in headlines.
Abbreviations must be limited primarily to those in general usage. Weights and measurements must be expressed in metric units. Temperatures must be expressed in degrees centigrade.
Illustrations, pictures and graphs, should be supplied with the highest quality and in an electronic format that helps us to publish your article in the best way possible. Please follow the guidelines below to enable us to prepare your artwork for the printed issue as well as the online version.
Format: TIFF, JPEG: Common format for pictures (containing no text or graphs).
EPS: Preferred format for graphs and line art (retains quality when enlarging/zooming in).
Placement: Figures/charts and tables created in MS Word should be included in the main text rather than at the end of the document.
Figures and other files created outside Word (i.e. Excel, PowerPoint, JPG, TIFF, EPS, and PDF) should be submitted separately. Please add a placeholder note in the running text (i.e. “[insert Figure 1.]")
Resolution: Rasterized based files (i.e. with .tiff or .jpeg extension) require a resolution of at least 300 dpi (dots per inch). Line art should be supplied with a minimum resolution of 800 dpi.
Color: Please note that images supplied in color will be published in color online and black and white in print (unless otherwise arranged). Therefore, it is important that you supply images that are comprehensible in black and white as well (i.e. by using color with a distinctive pattern or dotted lines). The captions should reflect this by not using words indicating color.
Dimension: Check that the artworks supplied match or exceed the dimensions of the journal. Images cannot be scaled up after origination
Fonts: The lettering used in the artwork should not vary too much in size and type (usually sans serif font as a default).
Figures and Tables
Manuscripts should contain no more than five total figures and tables. Additional figures and tables may be included in a supplement for web-only publication.
Tables may be included in the body of text in a Word document. They should be numbered consecutively (i.e., 1, 2, 3).
Tables must be editable as they will be styled to match the JPPA brand. Tables created in Microsoft Word or Excel are acceptable editable formats.
Figures must be submitted in electronic format. Figures must be cited in the text and numbered in order of mention. Figures must be numbered consecutively (i.e., 1, 2, 3). Multi-part figures must be marked clearly (e.g., 1A, 1B, 1C). They must be created with vector software such as Adobe Illustrator. Preferably, figures should be attached as separate documents, in addition to embedding them into Word documents. Please include file extensions when naming and saving files.
JPPA adheres to the AMA reference style. Please review the AMA guidelines to ensure your manuscript conforms to this reference style.
Try to limit references to those that are essential or most relevant. Number references in the order they appear in the text. In text, tables, and legends, indicate references with superscript Arabic numerals. When listing references, abbreviate names of journals according to Index Medicus. Please include full page range. Questions about references should be addressed to email@example.com.
List the first six authors; when there are more than six authors, list the first three authors followed by et al. Do not list only the first author followed by et al.
Manuscripts should contain no more than 75 references. Additional references may be included in a supplement for web-only publication.
Authors seeking assistance with English language editing, translation, or figure and manuscript formatting to fit the journal’s specifications should consider using SAGE Language Services. Visit SAGE Language Services on our Journal Author Gateway for further information.
JPPA is hosted on SAGE Track, a web based online submission and peer review system powered by ScholarOne™ Manuscripts. Visit https://mc.manuscriptcentral.com/JPPA to login and submit your article online.
IMPORTANT: Please check whether you already have an account in the system before trying to create a new one. If you have reviewed or authored for the journal in the past year it is likely that you will have had an account created. For further guidance on submitting your manuscript online please visit ScholarOne Online Help.
As part of our commitment to ensuring an ethical, transparent and fair peer review process SAGE is a supporting member of ORCID, the Open Researcher and Contributor ID. ORCID provides a unique and persistent digital identifier that distinguishes researchers from every other researcher, even those who share the same name, and, through integration in key research workflows such as manuscript and grant submission, supports automated linkages between researchers and their professional activities, ensuring that their work is recognized.
The collection of ORCID IDs from corresponding authors is now part of the submission process of this journal. If you already have an ORCID ID you will be asked to associate that to your submission during the online submission process. We also strongly encourage all co-authors to link their ORCID ID to their accounts in our online peer review platforms. It takes seconds to do: click the link when prompted, sign into your ORCID account and our systems are automatically updated. Your ORCID ID will become part of your accepted publication’s metadata, making your work attributable to you and only you. Your ORCID ID is published with your article so that fellow researchers reading your work can link to your ORCID profile and from there link to your other publications.
Please supply a title, short title, an abstract and keywords to accompany your article. The title, keywords and abstract are key to ensuring readers find your article online through online search engines such as Google. Please refer to the information and guidance on how best to title your article, write your abstract and select your keywords by visiting the SAGE Journal Author Gateway for guidelines on How to Help Readers Find Your Article Online.
You will be asked to provide contact details and academic affiliations for all co-authors via the submission system and identify who is to be the corresponding author. These details must match what appears on your manuscript. The affiliation listed in the manuscript should be the institution where the research was conducted. If an author has moved to a new institution since completing the research, the new affiliation can be included in a manuscript note at the end of the paper. At this stage please ensure you have included all the required statements and declarations and uploaded any additional supplementary files (including reporting guidelines where relevant).
Please also ensure that you have obtained any necessary permission from copyright holders for reproducing any illustrations, tables, figures or lengthy quotations previously published elsewhere. For further information including guidance on fair dealing for criticism and review, please see the Copyright and Permissions page on the SAGE Author Gateway.
Your SAGE Production Editor will keep you informed as to your article’s progress throughout the production process. Proofs will be made available to the corresponding author via our editing portal SAGE Edit or by email, and corrections should be made directly or notified to us promptly. Authors are reminded to check their proofs carefully to confirm that all author information, including names, affiliations, sequence and contact details are correct, and that Funding and Conflict of Interest statements, if any, are accurate. Please note that if there are any changes to the author list at this stage all authors will be required to complete and sign a form authorizing the change.
OnlineFirst allows final articles (completed and approved articles awaiting assignment to a future issue) to be published online prior to their inclusion in a journal issue, which significantly reduces the lead time between submission and publication. Visit the SAGE Journals help page for more details, including how to cite OnlineFirst articles.
SAGE provides authors with online access to their final article.
Publication is not the end of the process! You can help disseminate your paper and ensure it is as widely read and cited as possible. The SAGE Author Gateway has numerous resources to help you promote your work. Visit the Promote Your Article page on the Gateway for tips and advice.
Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to the JPPA editorial office: firstname.lastname@example.org.
Editors have very broad discretion in determining whether an article is an appropriate fit for their journal. Many manuscripts are declined with a very general statement of the rejection decision. These decisions are not eligible for formal appeal unless the author believes the decision to reject the manuscript was based on an error in the review of the article, in which case the author may appeal the decision by providing the Editor with a detailed written description of the error they believe occurred.
If an author believes the decision regarding their manuscript was affected by a publication ethics breach, the author may contact the publisher with a detailed written description of their concern, and information supporting the concern, at email@example.com.